Breast Cancer

Priority Review Granted for Pertuzumab for Previously Untreated HER2+ Metastatic Breast Cancer

Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA) for pertuzumab and granted Priority Review for use in combination with Herceptin (trastuzumab; Genentech) and docetaxel chemotherapy for people with HER2+ metastatic or locally recurrent, unresectable breast cancer, who have not received previous treatment or whose disease has relapsed after adjuvant therapy.

Cancer Prevention Guidelines Updated

The American Cancer Society (ACS) Nutrition and Physical Activity Guidelines were recently updated and published in the January/February issue of CA: A Cancer Journal for Clinicians.

Hormone Receptor Levels Predict Trastuzumab Effect

Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer whose tumors also express hormone receptors may be less responsive to the addition of trastuzumab to chemotherapy, suggesting that hormone receptor expression has a predictive role in determining response to therapy.

Breast Cancer Survivors Prefer Oncologist Follow-Up

In breast cancer survivors participating in a survivorship study, follow-up visits with an oncologist as compared to other types of clinicians are perceived to minimize stress around the visit, decrease worrying about cancer, and improve the self-perceived impact of follow-up visits on cancer survival.

Breast Cancer Survival Up With Everolimus + Exemestane

Everolimus plus exemestane improves progression-free survival (PFS) for postmenopausal women with hormone-receptor (HR)-positive breast cancer; and pertuzumab plus trastuzumab plus docetaxel improves PFS in human epidermal growth factor receptor type 2 (HER2)-positive metastatic breast cancer, according to two studies published online December 7, 2011 in the New England Journal of Medicine to coincide with presentation at the annual San Antonio Breast Cancer Symposium, held from December 6 to 10.